These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
521 related articles for article (PubMed ID: 35352187)
61. A case report to assess the safety and efficacy of Burosumab, an investigational antibody to FGF23, in a single pediatric patient with Epidermal Nevus Syndrome and associated hypophosphatemic rickets. Huynh C; Gillis A; Fazendin J; Abdullatif H Bone Rep; 2022 Dec; 17():101605. PubMed ID: 35899095 [TBL] [Abstract][Full Text] [Related]
62. Hypophosphatemic Rickets with R179W Mutation in FGFR23 Gene - A Rare But Treatable Cause of Refractory Rickets. Sandal S; Arora V; Verma IC Indian J Pediatr; 2021 Jan; 88(1):61-63. PubMed ID: 32415663 [TBL] [Abstract][Full Text] [Related]
63. Real-world effectiveness of burosumab in children with X-linked hypophosphatemic rickets. Paloian NJ; Nemeth B; Sharafinski M; Modaff P; Steiner RD Pediatr Nephrol; 2022 Nov; 37(11):2667-2677. PubMed ID: 35211790 [TBL] [Abstract][Full Text] [Related]
64. Diagnosis, treatment-monitoring and follow-up of children and adolescents with X-linked hypophosphatemia (XLH). Rothenbuhler A; Schnabel D; Högler W; Linglart A Metabolism; 2020 Feb; 103S():153892. PubMed ID: 30928313 [TBL] [Abstract][Full Text] [Related]
65. Treatment of X-linked hypophosphatemia with calcitriol and phosphate increases circulating fibroblast growth factor 23 concentrations. Imel EA; DiMeglio LA; Hui SL; Carpenter TO; Econs MJ J Clin Endocrinol Metab; 2010 Apr; 95(4):1846-50. PubMed ID: 20157195 [TBL] [Abstract][Full Text] [Related]
66. Vitamin D deficiency or resistance and hypophosphatemia. Sarathi V; Dhananjaya MS; Karlekar M; Lila AR Best Pract Res Clin Endocrinol Metab; 2024 Mar; 38(2):101876. PubMed ID: 38365463 [TBL] [Abstract][Full Text] [Related]
67. An Overview of Rickets in Children. Chanchlani R; Nemer P; Sinha R; Nemer L; Krishnappa V; Sochett E; Safadi F; Raina R Kidney Int Rep; 2020 Jul; 5(7):980-990. PubMed ID: 32647755 [TBL] [Abstract][Full Text] [Related]
68. Nationwide survey of fibroblast growth factor 23 (FGF23)-related hypophosphatemic diseases in Japan: prevalence, biochemical data and treatment. Endo I; Fukumoto S; Ozono K; Namba N; Inoue D; Okazaki R; Yamauchi M; Sugimoto T; Minagawa M; Michigami T; Nagai M; Matsumoto T Endocr J; 2015; 62(9):811-6. PubMed ID: 26135520 [TBL] [Abstract][Full Text] [Related]
69. Burosumab for X-linked hypophosphatemia in children and adolescents: Opinion based on early experience in seven European countries. Mughal MZ; Baroncelli GI; de Lucas-Collantes C; Linglart A; Magnolato A; Raimann A; Santos F; Schnabel D; Shaw N; Nilsson O Front Endocrinol (Lausanne); 2022; 13():1034580. PubMed ID: 36798486 [TBL] [Abstract][Full Text] [Related]
70. Clinical spectrum and diagnostic challenges of vitamin D dependent rickets type 1A (VDDR1A) caused by Aftab S; Khan SA; Malik MI; Imran A; Anjum MN; Saeed A; Qureshi AA; Cheema HA J Pediatr Endocrinol Metab; 2023 Feb; 36(2):152-157. PubMed ID: 36524979 [TBL] [Abstract][Full Text] [Related]
71. [Updates on rickets and osteomalacia: the therapy for FGF23 related rickets]. Yamamoto T Clin Calcium; 2013 Oct; 23(10):1491-6. PubMed ID: 24076648 [TBL] [Abstract][Full Text] [Related]
72. Real-world data of Brazilian adults with X-linked hypophosphatemia (XLH) treated with burosumab and comparison with other worldwide cohorts. Vaisbich MH; de Cillo ACP; Silva BCC; DÁlva CB; de Carvalho ÉH; de Almeida JMCM; Marques LLM; Ribeiro M; da Silva MBM; de Medeiros PFV; Mendes PH Mol Genet Genomic Med; 2024 Feb; 12(2):e2387. PubMed ID: 38337160 [TBL] [Abstract][Full Text] [Related]
73. Hypophosphatemic rickets and short stature. Davis K; Imel EA; Kelley J J Bone Miner Res; 2024 Aug; 39(7):821-825. PubMed ID: 38988138 [TBL] [Abstract][Full Text] [Related]
74. Effect of Burosumab Compared With Conventional Therapy on Younger vs Older Children With X-linked Hypophosphatemia. Ward LM; Glorieux FH; Whyte MP; Munns CF; Portale AA; Högler W; Simmons JH; Gottesman GS; Padidela R; Namba N; Cheong HI; Nilsson O; Mao M; Chen A; Skrinar A; Roberts MS; Imel EA J Clin Endocrinol Metab; 2022 Jul; 107(8):e3241-e3253. PubMed ID: 35533340 [TBL] [Abstract][Full Text] [Related]
75. Fibroblast growth factor 23 and its receptors. Yu X; White KE Ther Apher Dial; 2005 Aug; 9(4):308-12. PubMed ID: 16076372 [TBL] [Abstract][Full Text] [Related]
76. Sex differences of burosumab in children with X-linked hypophosphataemic rickets. Filler G; Tremblay O; Chen E; Huang SSH; Stein R Pediatr Nephrol; 2023 Sep; 38(9):3183-3187. PubMed ID: 36542147 [TBL] [Abstract][Full Text] [Related]
77. Hereditary hypophosphatemic rickets with hypercalciuria: case report. Areses-Trapote R; López-García JA; Ubetagoyena-Arrieta M; Eizaguirre A; Sáez-Villaverde R Nefrologia; 2012 Jul; 32(4):529-34. PubMed ID: 22806288 [TBL] [Abstract][Full Text] [Related]
78. FGF23-FGF Receptor/Klotho Pathway as a New Drug Target for Disorders of Bone and Mineral Metabolism. Fukumoto S Calcif Tissue Int; 2016 Apr; 98(4):334-40. PubMed ID: 26126937 [TBL] [Abstract][Full Text] [Related]
79. Hereditary hypophosphatemic rickets with hypercalciuria: a study for the phosphate transporter gene type IIc and osteoblastic function. Yamamoto T; Michigami T; Aranami F; Segawa H; Yoh K; Nakajima S; Miyamoto K; Ozono K J Bone Miner Metab; 2007; 25(6):407-13. PubMed ID: 17968493 [TBL] [Abstract][Full Text] [Related]
80. Efficacy of Burosumab Every 2 Weeks in an Adult with X-Linked Hypophosphatemia: Should We Learn from Children? Marcellino A; Bloise S; Pirone C; Brandino G; Gizzone P; Fraternali R; Dilillo A; Del Giudice E; Martucci V; Sanseviero M; Rita LM; Ventriglia F; Lubrano R Monoclon Antib Immunodiagn Immunother; 2023 Jun; 42(3):104-108. PubMed ID: 37343168 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]